The following sets forth some of our Group's key business development milestones:

Picture

Shenyang Sunshine, our major operating subsidiary, was established in the PRC.

1993
Picture

Intefen, our recombinant interferon alpha-2a product was launched.

1995
Picture

Inleusin, our recombinant human interleukin 2 product, one of the first interleukin products introduced in the PRC market, was launched.

1996
Picture

EPIAO, our core injectable recombinant human EPO product, was launched in China.

1998
Picture

EPIAO became the number one rhEPO product in China in terms of both sales volume and revenue.

2002
Picture

TPIAO, a recombinant human TPO and another of our core products, besides EPIAO, was approved by the CFDA. It remains the first and only approved rhTPO product in China.

2005
Picture

Our Company was incorporated as an exempted company with limited liability in the Cayman Islands.

2006
Picture

Through Liaoning Sunshine, we obtained a five-year exclusive license to distribute IV Iron Sucrose, an iron supplement product that is now our third largest revenue generator after EPIAO and TPIAO, in the PRC.

2006
Picture

Our Company was listed on the NASDAQ.

2007
Picture

We completed the construction of additional manufacturing facilities for EPIAO and TPIAO in the Shenyang Economy and Technology Development Zone. The facilities received CFDA certification and conformed to requirements of major international regulatory guidelines including those of the European Medicines Agency and the Pharmaceutical Cooperation Inspection Scheme. The facilities enabled us to increase our manufacturing capacity of EPIAO and TPIAO by approximately four times.

2010
Picture

The CFDA approved our voluntary upgrade of manufacturing specifications to fully align the product quality of EPIAO with European Pharmacopoeia standards.

2010
Picture

Our Company was privatized and ceased to be listed on the NASDAQ.

2013
Picture

We acquired Sciprogen, a biopharmaceutical company based in China. We also acquired Sirton, a contract-based pharmaceutical manufacturer based in Italy.

Separately, we entered into a strategic cooperation agreement with and acquired approximately 6.96% equity interest in CP Guojian.

2014